Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Objective: Evaluate the efficacy and physiological effects of sublingual buprenorphine
(SL-BUP; Subutex) combined with extended-release injectable naltrexone (XR-NTX; Vivitrol) in
the treatment alcohol use disorder of comorbid (AUD) and post-traumatic stress disorder
(PTSD)
Phase:
Phase 2
Details
Lead Sponsor:
Pharmacotherapies for Alcohol and Substance Abuse Consortium
Collaborators:
RTI International United States Department of Defense